BioSpace News Archive

These results are the first reported demonstration of rapid and robust treatment changes in key disease markers associated with the severity of disease.

Prospective multicenter trial for the Unyvero UTI panel recruited its 1,000th prospective patient sample.

Mindset Pharma Inc. today announced that the Company has entered into an innovative research collaboration with the Centre for Addiction and Mental Health (“CAMH”).

Zucara Therapeutics Inc. today announced that its Phase 1b proof-of-concept trial demonstrated ZT-01’s ability to restore glucagon release in people with Type 1 diabetes (“T1D”).

Arch Therapeutics, Inc. (OTCQB: ARTH) (“ Arch ” or the “ Company ”), a marketer and developer of novel self-assembling wound care and biosurgical products, today provided an update regarding its reimbursement strategy for the use of AC5 ® Advanced Wound System (“AC5”), specifically regarding its use in doctor’s offices and wound clinics.

Alpha Cognition Inc. today announced positive results from its pivotal bioequivalence study with ALPHA-1062, a proprietary, delayed release oral tablet formulation in development for the treatment of mild to moderate Alzheimer’s Disease (AD).

IMV achieves predetermined milestone to access the remaining $US10 Million under its Debt Facility with Horizon.

Superior Clinical Outcomes for Nociscan TM Proving to be Durable at Two Years Two Year Results and the Schedule of Future Clinical Trials to be Outlined at the Annual State of Spine Surgery Think Tank 2022

Biocept’s CNSide™ assay provides a highly sensitive method to assess and quantify tumor cell burden in leptomeningeal metastasis (LM) of the central nervous system.

BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX) , a clinical stage company focused on stem cell-based therapies, today announced it has reached an agreement with its second clinical site for its Phase 2 clinical trial targeting chronic lumbar disc disease (cLDD).